Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

This peer was Novo Nordisk, which like Eli Lilly sells a popular drug approved specifically for obesity. Eli Lilly's recent popularity is due in no small measure to its plunge into the highly ...

Eli Lilly and Company (LLY) on Tuesday said that its cancer drug Jaypirca was more effective than AbbVie’s drug Imbruvica in ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Talking about Morgan Stanley’s bullish call on Eli Lilly and Company (NYSE:LLY), Kevin Simpson, Capital Wealth Planning ...

We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY ...

Eli Lilly isn't done in developing new weight loss treatments. In fact, the best may still be to come, as it's working on a pill, which could be a game changer for the industry.

Key Points Visa, Netflix and Eli Lilly are moving closer to the trillion dollar club. While all three have the potential, one will reach $3 trillion sooner than the others.